Funding (Selection):

CardioReGenix:

Development of Next-Generation Gene Therapies for Cardiovascular Disease

Duration: January 1, 2019 - June 30, 2024


TRAIN-HEART:

RNA therapeutics for heart failure, European training Network

A Marie Sklodowska-Curie Innovative Training Network for 15 PhD fellows

Duration: 2019 - August 2023


SFB1470 HFpEF:

Multilevel mechanistic characterization of Heart Failure with Preserved Ejection Fraction - Towards a novel classification of HFpEF for targeted therapies.


FIBREX:

Targeting cardiac fibrosis with next generation RNA therapeutics

Duration: August 2022 - May 2025


ERC Advanced Grant REVERSE:

Circular RNAs to reverse pathological remodelling of the injured heart

Duration: October 1, 2022 - September 30, 2027


COFONI:

Investigation of circular RNAs as mediators of SARS-CoV-2 infection in the cardiovascular system

Duration: February 2022 - January 2025


TransRegio/SFB 267:

"Non-coding RNA in the cardiovascular system"

Sub-Project B01 "CircRNAs in postnatal heart development and cardiac disease"


INNOVATION:

Investigating long non-coding RNA regulated pathways driving cardiac regeneration

Duration: 2019 - December 2023

 


More:

  • EU projects:

  1. HOMAGE: Heart OMics in AGEing (2013 - 2019)
  2. ERC Consolidator Grant LONGHEART: Exploring selected long non-coding RNAs as diagnostics and therapeutic targets for heart failure (2015 - 2020)
  3. EU funding via N-Bank - as part of the Lower Saxony innovation funding program for research and development in companies: Development of a cardiomyocyte-specific CHAST therapy for the treatment of chronic heart failure (together with Cardior Pharmaceuticals GmbH, 2018 - 2021)
  4. ERC Proof-of-Concept Grant MEGFIB: Preclinical development of lncRNA-meg3 inhibitors to treat cardiac fibrosis (2020 - 2021)

 

  • Leducq Foundation:

Trans-Atlantic Network and Training Program on MicroRNA-Based Therapeutic Strategies in Vascular Disease

(MIRVAD, 2014 - 2019)

 

  • DFG:

  1. TH903/18-1 (with ANR): Regulation, diagnostics and therapy focusing on the mineralocorticoid receptor involved in cardiac remodeling (2016 - 2020)
  2. TH903/19-1 (with ANR): CARDINAL - Cardiomyocyte-derived vesicular non coding RNAs and post-ischemic cardiac remodeling (2016 - 2020)
  3. TH903/20-1(KFO 311): (Pre-)terminal heart and lung failure: mechanical unloading and repair, subproject 9 (2016 - 2019)
  4. TH903/22-1(FOR 2591): Severity assessment in animal based research (2017 - 2020)
  5. BA5631/2-1: Functional and molecular analysis of telomerase in cardiomyocyte proliferation and heart regeneration (2017 - 2020)
  6. DFG Hoepfner (HO 6855/1-1) - Deciphering the role of miRNAs in Fabry disease pathology and therapy (March 2021 - February 2024)
  7. DFG Jung (JU 3222/2-1) - The molecular role of selected circRNAs in cardiac macrophage dynamics and inflammatory response during cardiac remodeling after myocardial infarction (June 2021 - May 2024)
  8. DFG Bär/Brandenberger (BA 5631/5-1) - "Targeting telomere dysfunction-related immune- and organ senescence in pulmonary and cardiovascular disease" (April 2023 - March 2026)

 

  • European Research Area Network (ERA-Net) projects:

ERA-CVD/BMBF, Project Management Agency DLR

  1. EXPERT: Exploring new pathways in age-related heart diseases (Analysis of RNA-based signaling pathways in age-related heart diseases; 2017 - 2020) *
  2. LIPCAR: LIPCAR, a prognostic marker of heart failure with reduced ejection fraction (LIPCAR, a prognostic biomarker in heart failure; 2017 - 2020)

 

  • Else Kröner-Fresenius Foundation (EKFS):

Else Kröner Medical Scientist Kollegs 2022: nextGENERATION: ReGENERAte Organ FunctION

  1. Natalie Weber; Stem cell-based regenerative therapies of cardiac diseases (July 2023 - July 2026)

 

  • Industry (different projects):

* co-ordinating party

 

  • Further cooperations:

COST CardioRNA